ReviewMolecules (Basel, Switzerland)2022
Stimuli-Responsive Drug Delivery Systems for the Diagnosis and Therapy of Lung Cancer.
Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Advancing Tuberculosis Treatment with Next-Generation Drugs and Smart Delivery Systems.Pharmaceutics · 2026Review
- Precision theranostics in cervical Cancer: Harnessing stimuli-responsive hydrogels for tumor microenvironment-targeted therapy and diagnosis.Materials today. Bio · 2025Review
- Review
- Impact of pH-Responsive Cisplatin/Ribavirin-Loaded Monodispersed Magnetic Silica Nanocomposite on A549 Lung Cancer Cells.Pharmaceutics · 2025Article
- Smart nanoplatforms for early detection and immune modulation in lung cancer.Frontiers in bioengineering and biotechnology · 2025Review
- Intelligent Drug Delivery: Pioneering Stimuli-Responsive Systems to Revolutionize Disease Management- An In-depth Exploration.Current drug delivery · 2025Review
- CD44 targeted functionalized nanocarriers for non-small cell lung cancer.Frontiers in oncology · 2025Review
- Unveiling innovative therapeutic strategies and future trajectories on stimuli-responsive drug delivery systems for targeted treatment of breast carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Responsive Supramolecular Polymers for Diagnosis and Treatment.International journal of molecular sciences · 2024Review
- Controlled Sr(ii) ion release fromRSC advances · 2024Article
- Structural Determinants of Stimuli-Responsiveness in Amphiphilic Macromolecular Nano-assemblies.Progress in polymer science · 2024Article
- L-Lysine-Modified pNIPAm-co-GMA Copolymer Hydrogel for pH- and Temperature-Responsive Drug Delivery and Fluorescence Imaging Applications.Gels (Basel, Switzerland) · 2023Article
- Exosomes and ultrasound: The future of theranostic applications.Materials today. Bio · 2023Review
- Charge-Convertible and Reduction-Sensitive Cholesterol-Containing Amphiphilic Copolymers for Improved Doxorubicin Delivery.Materials (Basel, Switzerland) · 2022Article
- Ultrasound-Induced Drug Release from Stimuli-Responsive Hydrogels.Gels (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide. Numerous drugs have been developed to treat lung cancer patients in recent years, whereas most of these drugs have undesirable adverse effects due to nonspecific distribution in the body. To address this problem, stimuli-responsive drug delivery systems are imparted with unique characteristics and specifically deliver loaded drugs at lung cancer tissues on the basis of internal tumor microenvironment or external stimuli. This review summarized recent studies focusing on the smart carriers that could respond to light, ultrasound, pH, or enzyme, and provided a promising strategy for lung cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.